These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37951220)

  • 61. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
    Yokoyama K; Yamazaki K; Katafuchi M; Ferchichi S
    Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn's disease.
    Chen L; Lu Z; Kang D; Feng Z; Li G; Sun M; Liu Z; Wu W; Fang L
    Front Pharmacol; 2022; 13():913720. PubMed ID: 36034848
    [No Abstract]   [Full Text] [Related]  

  • 63. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dose escalation of biologics in Crohn's disease: critical review of observational studies.
    Einarson TR; Bereza BG; Ying Lee X; Lelli F
    Curr Med Res Opin; 2017 Aug; 33(8):1433-1449. PubMed ID: 28537467
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease.
    Carlsen A; Omdal R; Karlsen L; Kvaløy JT; Aabakken L; Steinsbø Ø; Bolstad N; Warren D; Lundin KEA; Grimstad T
    JGH Open; 2020 Jun; 4(3):410-416. PubMed ID: 32514446
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.
    Dreesen E; Baert F; Laharie D; Bossuyt P; Bouhnik Y; Buisson A; Lambrecht G; Louis E; Oldenburg B; Pariente B; Pierik M; van der Woude CJ; D'Haens G; Vermeire S; Gils A
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):637-646.e11. PubMed ID: 31128336
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
    Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
    J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study.
    Wlazło M; Meglicka M; Wiernicka A; Osiecki M; Kierkuś J
    Children (Basel); 2022 Dec; 10(1):. PubMed ID: 36670562
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.
    Patil SA; Rustgi A; Langenberg P; Cross RK
    Dig Dis Sci; 2013 Jan; 58(1):209-15. PubMed ID: 23014844
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study.
    Bastida G; Marín-Jiménez I; Forés A; García-Planella E; Argüelles-Arias F; Tagarro I; Fernandez-Nistal A; Montoto C; Aparicio J; Aguas M; Santos-Fernández J; Boscá-Watts MM; Ferreiro-Iglesias R; Merino O; Aldeguer X; Cortés X; Sicilia B; Mesonero F; Barreiro-de Acosta M
    Dig Liver Dis; 2022 Jan; 54(1):76-83. PubMed ID: 34244110
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease.
    Hinojosa J; Muñoz F; Martínez-Romero GJ
    Dig Dis; 2019; 37(6):444-450. PubMed ID: 31039560
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease.
    Lehtomäki J; Nikkonen A; Merras-Salmio L; Hiltunen P; Kolho KL
    Scand J Gastroenterol; 2022 Jan; 57(1):31-36. PubMed ID: 34546843
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adalimumab and Infliximab in Crohn's disease - real life data from a national retrospective cohort study.
    Preda C; Fulger L; Gheorghe L; Gheorghe C; Goldis A; Trifan A; Tantau M; Tantau A; Negreanu L; Manuc M; Cijevschi-Prelipcean C; Iacob R; Tieranu C; Meianu C; Diculescu M
    Curr Health Sci J; 2016; 42(2):115-124. PubMed ID: 30568821
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G; Vermeire S; Lambrecht G; Baert F; Bossuyt P; Pariente B; Buisson A; Bouhnik Y; Filippi J; Vander Woude J; Van Hootegem P; Moreau J; Louis E; Franchimont D; De Vos M; Mana F; Peyrin-Biroulet L; Brixi H; Allez M; Caenepeel P; Aubourg A; Oldenburg B; Pierik M; Gils A; Chevret S; Laharie D;
    Gastroenterology; 2018 Apr; 154(5):1343-1351.e1. PubMed ID: 29317275
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
    Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
    Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn's Disease: A Cross-Sectional Multicentric Latin American Study.
    de Souza LR; Magro DO; Teixeira FV; Parra RS; Miranda EF; Féres O; Saad-Hossne R; Soares Prates Herrerias G; Nisihara RM; Coy CSR; Sassaki LY; Kotze PG
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839908
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Effect of Adiposity on Anti-Tumor Necrosis Factor-Alpha Levels and Loss of Response in Crohn's Disease Patients.
    Lim Z; Welman CJ; Raymond W; Thin L
    Clin Transl Gastroenterol; 2020 Sep; 11(9):e00233. PubMed ID: 33094963
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.
    Juncadella A; Papamichael K; Vaughn BP; Cheifetz AS
    Dig Dis Sci; 2018 Nov; 63(11):3067-3073. PubMed ID: 30006816
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study.
    Thorne C; Boire G; Chow A; Garces K; Liu F; Poulin-Costello M; Walker V; Haraoui B
    Open Rheumatol J; 2017; 11():123-135. PubMed ID: 29296125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.